Mucopolysaccharidosis VI Clinical Trial
— iMProveSOfficial title:
A Phase IIa Study to Investigate Safety, Pharmacokinetics, and Efficacy of Odiparcil in Patients 16 Years and Above With Mucopolysaccharidosis (MPS) Type VI
Verified date | October 2019 |
Source | Inventiva Pharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Mucopolysaccharidoses (MPS) are a group of rare inherited disorders characterized by a
deficiency of lysosomal enzymes responsible for the normal degradation of glycosaminoglycans
(GAGs). Medical need for treatment of MPS is still very high due to the poor penetration of
the recombinant enzymes into the blood brain barrier as well as the ocular barriers and into
tissues that are poorly vascularized, such as cartilages and bones. Odiparcil is an orally
active compound that allows the synthesis of soluble glycosaminoglycans (GAGs), mainly
chondroitin sulfate (CS) and dermatane sulfate (DS). The neosynthesized solubles GAGs are
then excreted in urine. By diverting endogenous GAG synthesis to the synthesis of soluble
odiparcil linked GAGs, odiparcil should decrease the intracellular pool of GAGs and
consequently decrease the lysosomal GAG accumulation.
The primary objective of the study is to assess the safety and efficacy of two doses of
odiparcil in MPS VI patients and to provide evidence to enable the selection of the relevant
dose of odiparcil for phase III study. The secondary objective of this study is to
characterize the dose response, PK and PD of odiparcil.
Status | Completed |
Enrollment | 20 |
Est. completion date | October 22, 2019 |
Est. primary completion date | September 24, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility |
1. Male or female gender. 2. Age =16 years. 3. Diagnosis of MPS VI, demonstrated by a reduced Arylsulfatase B (ARSB) activity relative to the normal range of the laboratory performing the assay in either white blood cells or fibroblast culture or confirmation of two known disease causing mutations in the ARSB gene. 4. Urine GAG above upper limit of normal (ULN) based on historical data. 5. Willing and able to provide written, dated, signed informed consent, or in the case of subjects age < 18 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures or study assessment. 6. Able to comply with all study procedures. 7. Women with childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy) must agree to use a highly effective method of birth control during the study and at least 4 weeks after last administration. The following can be considered to be examples of highly effective methods of contraception preferably with low user dependency: - Combined (estrogen and progestogen containing hormonal contraception) associated with inhibition of ovulation (oral, intravaginal, or transdermal) - Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable ) - intrauterine device (IUD)1 - intrauterine hormone-releasing system (IUS) 1 - Bilateral tubal occlusion1 - Vasectomised partner1 - Sexual abstinence These methods of contraception must be supplemented with a barrier method (preferably male condom). Women with childbearing potential are required to have a confirmed negative blood pregnancy test before starting medication administration at baseline (V0). Women with childbearing potential agree to repeat blood pregnancy tests at visits in hospital (V2, V4, V7 and V8) and to perform urine pregnancy test before each phone call visit (V3, V5 and V6). Inclusion criteria for ERT treated group: 1. Patients with MPS Type VI receiving enzyme replacement therapy (Naglazyme) for at least 6 months on the licensed dosage or as per local guidelines. Inclusion criteria for not ERT treated group: Patients with MPS Type VI not receiving enzyme replacement therapy for the following reasons: 1. Patients previously treated with ERT but have discontinued for more than 3 months either due to medical decision or personal choice 2. Patients allergic to ERT therapy 3. Patients that have had a previous hematopoietic stem cell transplant (HSCT) 4. Patients not treated with ERT i.e. treatment naïve Exclusion criteria: Exclusion criteria for the entire cohort: 1. Use of any investigational product or investigational medical device within 30 days prior to screening. This will include product bought over the counter specifically compounds like genistein and pentosane polysulphate which may not be considered as investigational products by patients and some health care professionals. 2. Concurrent disease or condition that would interfere with study participation or pose a safety concern for example patient with: severe cardiac insufficiency as define NYHA class > II, and severe restrictive chronic respiratory insufficiency as reflected by serum [HCO3-] =28 mEq/L. 3. Subjects who had surgery within 3 months before study starts, or for whom surgery is planned during study period. 4. Patient with spinal cord compression requiring surgical intervention. 5. Subjects with the following liver test anomalies: any ALT, AST > 3xULN or bilirubin >1.5xULN (except if Gilbert syndrome) at screening visit. 6. Evidence of an immunosuppressive state, including known HIV infection, agammaglubilinemias, T-Cell deficiencies. 7. Subjects with history of chronic infections, including but not limited to subjects with past history of viral hepatitis C, or B, with recent history of serious or life-threatening infection or any current signs or symptoms that may indicate infection at visit V-1 of study as per investigators clinical judgement. 8. History of malignant cancer except of cervical carcinoma in situ, basal cell carcinoma, dermatological squamous cell carcinoma. 9. Subjects with significant haematologic abnormalities, such as haemoglobin <8 g/dL, or WBC<2000 /mm3 or absolute neutrophil count <1300 /mm3, or platelet <30.000 /mm3. 10. International Normalized Ratio (INR), activated partial thromboplastin time (aPTT) or thrombin time (TT) values above the laboratory reference range at screening. For patients on anti-coagulants, they should be within their target effect on INR and be stable. 11. Any history of bleeding diathesis 12. Patient with coexistence of corneal pathologies other than corneal clouding (e.g. exposure keratopathy) 13. An unwillingness on the part of male patients to abstain from sexual intercourse with pregnant or lactating women; or an unwillingness to use highly effective form of birth control if engaging in sexual intercourse with a woman who could become pregnant from the time of the first dose of study medication until completion of follow-up procedures. 14. An unwillingness on the part of female patients to use highly effective form of birth control2 if engaging in sexual intercourse and to have a monthly pregnancy test during treatment and until completion of follow-up procedures. 15. Pregnant or lactating women. 16. Have a known hypersensitivity to any of the ingredients or excipients of the IMP including: Microcrystalline Cellulose, Povidone, Sodium starch glycolate (type A), Magnesium stearate, Opadry™ II 85F18422 Exclusion criteria for ERT treated group: 1. Previous hematopoietic stem cell transplant (HSCT) |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Femme-Mère-Enfant | Bron | |
Germany | Villa Metabolica | Mainz | |
Portugal | Centro Hospitalar S. João | Porto | |
United Kingdom | Royal Free Hospital | London |
Lead Sponsor | Collaborator |
---|---|
Inventiva Pharma |
France, Germany, Portugal, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients with modified clinical signs | Changes in physical examination and vital signs | 26 weeks | |
Primary | Number of patients with modified biological values | Change from baseline in laboratory safety tests (coagulation, liver enzymes and crystalluria) 12-lead-ECG and bone biomarkers. | 26 weeks | |
Primary | Incidence of AEs/SAEs | Incidence of AEs/SAEs, patient withdrawals from study due to AEs/SAEs, | 26 weeks | |
Primary | 12-lead ECG | Change from Baseline in ECG | 26 weeks | |
Secondary | Mobility: 6-minute walk test | Change from baseline in 6-minute walk test | 26 weeks | |
Secondary | Mobility: 9-hole PEG test | Change from baseline in 9-hole PEG test | 26 weeks | |
Secondary | Mobility: range of motion of the shoulder | Change from baseline in range of motion of the shoulder | 26 weeks | |
Secondary | Pain assessment | Change from Baseline in Brief Pain Inventory (BPI) | 26 weeks | |
Secondary | Respiratory function | Change from Baseline in FEV1 | 26 weeks | |
Secondary | Respiratory function | Change from Baseline in FVC | 26 weeks | |
Secondary | Respiratory function | Change from Baseline in MVV | 26 weeks | |
Secondary | Cardiac and vascular function | Change from Baseline in echocardiogram | 26 weeks | |
Secondary | Cardiac and vascular function | Change from Baseline in carotid intima media thickness Odiparcil concentration remaining in patient plasma 12 hours following the last intake of investigational product at visits V4 and V7. An identification of odiparcil metabolites in plasma at visit V2. | 26 weeks | |
Secondary | Audiology assessments | Change from Baseline in pure tone audiometry | 26 weeks | |
Secondary | Audiology assessments | Change from Baseline in whisper voice test | 26 weeks | |
Secondary | Ophthalmology assessments | Change from Baseline in corneal opacification | 26 weeks | |
Secondary | Ophthalmology assessments | Change from Baseline in level of retinopathy | 26 weeks | |
Secondary | Ophthalmology assessments | Change from Baseline in optic nerve involvement, | 26 weeks | |
Secondary | Ophthalmology assessments | Change from Baseline in intra-ocular pressure | 26 weeks | |
Secondary | Ophthalmology assessments | Change from Baseline in visual acuity | 26 weeks | |
Secondary | Quality of life questionnaires | Change from Baseline in EQ-5D-5L questionnaires. 5 dimensions scored on a 5-point scale will be assessed: mobility, self-care, usual activities, pain/discomfort, anxiety/depression | 26 weeks | |
Secondary | Quality of life questionnaires | Change from Baseline in Zarit caregiver burden questionnaires. Scale in 22 items scored on a 5-point scale with 0 = never and 5 = nearly always | 26 weeks | |
Secondary | Quality of life questionnaires | Change from Baseline in Fatigue Severity Scale questionnaires. 9 questions scored on a 7-point scale with 1 = strongly disagree and 7= strongly agree | 26 weeks | |
Secondary | Pharmacokinetics: odiparcil concentration in plasma | Odiparcil concentration in plasma at visit V2 (up to 12 hours post dose). | 12 hours | |
Secondary | ¨Pharmacodynamics: GAG concentrations | GAG concentration in leukocytes isolated from peripheral | 26 weeks | |
Secondary | ¨Pharmacodynamics: GAG concentrations | GAG concentrations in urine | 26 weeks | |
Secondary | Pharmacodynamics: GAG concentrations | GAG concentrations in skin | 26 weeks | |
Secondary | ¨Pharmacodynamics: anti-thrombin activity IIa | Change from Baseline in anti-thrombin activity IIa in plasma | 26 weeks | |
Secondary | ¨Pharmacodynamics: Thrombin Generation Assay (TGA) | Change from Baseline in TGA in plasma | 26 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01675674 -
Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics
|
N/A | |
Completed |
NCT00067470 -
Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI
|
Phase 3 | |
Completed |
NCT00048620 -
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
|
Phase 1 | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Completed |
NCT01707433 -
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
|
N/A | |
Active, not recruiting |
NCT03632213 -
Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI
|
Phase 2 | |
Terminated |
NCT00748969 -
Clinical Trial of Growth Hormone in MPS I, II, and VI
|
Phase 2/Phase 3 | |
Recruiting |
NCT05619900 -
Registry of Patients Diagnosed With Lysosomal Storage Diseases
|
||
Completed |
NCT00299000 -
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
|
Phase 4 | |
Completed |
NCT00176917 -
Stem Cell Transplantation for Hurler
|
Phase 2 | |
Enrolling by invitation |
NCT05368038 -
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
|
||
Completed |
NCT00048711 -
Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI
|
Phase 2 | |
Active, not recruiting |
NCT03153319 -
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
|
Phase 1/Phase 2 | |
Completed |
NCT00104234 -
Study of rhASB in Patients With Mucopolysaccharidosis VI
|
Phase 3 | |
Recruiting |
NCT06036693 -
MPS (RaDiCo Cohort) (RaDiCo-MPS)
|
||
Active, not recruiting |
NCT00005900 -
Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT01586455 -
Human Placental-Derived Stem Cell Transplantation
|
Phase 1 |